Johnson & Johnson lifted the low end of its guidance and posted better-than-anticipated results in the latest quarter as the health-care giant’s pharmaceutical business continues to buoy its top line.
from WSJ.com: US Business http://ift.tt/2dYlxGM
via IFTTT
No comments:
Post a Comment